All PlansAdministrativeMedium impact
Recall: Dabigatran
UPMC Health Plan·Cardiology, Internal Medicine, Family Medicine +2 more·Pharmacy
We identified it
Jun 20, 2026
Summary
Ascend Laboratories LLC has recalled 10 lots of Dabigatran capsules due to excessive nitrosamine levels above safety limits. Healthcare providers should immediately identify patients using recalled lots and coordinate with pharmacies for alternative anticoagulant therapy.
Action Required
Immediately: Clinical staff should review patient medication lists to identify those prescribed Dabigatran from Ascend Laboratories. Contact affected patients to coordinate with their pharmacy for lot number verification and alternative anticoagulant options if using recalled lots. Document any medication changes in patient records.